Journal article
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
- Abstract:
- Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
- Publisher:
- Remedy Publications LLC
- Journal:
- Clinics in Oncology More from this journal
- Volume:
- 2
- Article number:
- 1183
- Publication date:
- 2017-01-05
- Acceptance date:
- 2017-01-03
- ISSN:
-
2474-1663
- Pmid:
-
30613826
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:958262
- UUID:
-
uuid:a28b73d6-9d41-4476-a9e8-dc90b94fb5c4
- Local pid:
-
pubs:958262
- Source identifiers:
-
958262
- Deposit date:
-
2019-04-26
Terms of use
- Copyright holder:
- Rabbitts et al
- Copyright date:
- 2017
- Notes:
-
Copyright © 2017 Rabbitts T. This is an open access article distributed under
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record